Phenominer Database Results (9 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Time Value Method Notes Record ID Study ID
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91 days-112 days 13 69.0 % in vivo visual assessment 0.0 0 68123 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65 days-112 days 21 11.7 d 2.23 10.2 in vivo visual assessment 0.0 0 69490 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 13 22.5 d 3.58 12.9 in vivo visual assessment 0.0 0 69492 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 13 10.1 d 2.63 9.5 in vivo visual assessment 0.0 0 69377 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 91 days-112 days 21 76.0 % in vivo visual assessment 0.0 0 visual observation 69488 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 0 22.5 d 12.9 in vivo visual assessment 0.0 0 69500 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 0 10.1 d 9.5 in vivo visual assessment 0.0 0 69502 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65 days-112 days 21 21.9 d 2.47 11.3 in vivo visual assessment 0.0 0 69494 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91 days-112 days 0 69.0 % 48.0 in vivo visual assessment 0.0 0 visual observation 69498 837